CML IDST
Expert Guidance on Monitoring Response to BCR-ABL1 Inhibitors in CML: An Interactive Decision Support Tool

Released: January 07, 2025

Expiration: January 06, 2026

Daniel J. DeAngelo
Daniel J. DeAngelo, MD, PhD
Michael J. Mauro
Michael J. Mauro, MD
Neil P. Shah
Neil P. Shah, MD, PhD
B. Douglas Smith
B. Douglas Smith, MD
Tiffany N. Tanaka
Tiffany N. Tanaka, MD

Introduction

Use this interactive tool to gain expert guidance on monitoring response to BCR-ABL1 inhibitors in CML, adapting treatment based on response and adverse events, and when to consider treatment-free remission.

Interactive Decision Support Tool

Expert Guidance on Monitoring Response to BCR-ABL1 Inhibitors in CML: An Interactive Decision Support Tool

Disclaimer

Access to and use of this Interactive Decision Support Tool titled, “Expert Guidance on Monitoring Response to BCR-ABL1 Inhibitors in CML: An Interactive Decision Support Tool” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on the optimal management of patients with CML in chronic phase using TKIs. The information provided is based on guideline recommendations and expert guidance of Daniel J. DeAngelo, MD, PhD; Michael J. Mauro, MD; Neil P. Shah, MD, PhD; B. Douglas Smith, MD; and Tiffany N. Tanaka, MD.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Expert Guidance on Monitoring Response to BCR-ABL1 Inhibitors in CML: An Interactive Decision Support Tool” has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

©2025 Clinical Care Options, LLC. All rights reserved.

Program Content